Krystal Biotech, Inc. (KRYS)
305.19
-0.49
(-0.16%)
USD |
NASDAQ |
Nov 13, 16:00
305.19
0.00 (0.00%)
After-Hours: 19:59
Krystal Biotech Net Income (Quarterly) : 63.07M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 63.07M |
| June 30, 2026 | 54.77M |
| March 31, 2026 | 55.93M |
| December 31, 2025 | 51.40M |
| September 30, 2025 | 79.36M |
| June 30, 2025 | 38.33M |
| March 31, 2025 | 35.73M |
| December 31, 2024 | 45.48M |
| September 30, 2024 | 27.18M |
| June 30, 2024 | 15.57M |
| March 31, 2024 | 0.932M |
| December 31, 2023 | 8.692M |
| September 30, 2023 | 80.75M |
| June 30, 2023 | -33.21M |
| March 31, 2023 | -45.30M |
| December 31, 2022 | -32.05M |
| September 30, 2022 | -29.85M |
| June 30, 2022 | -28.11M |
| March 31, 2022 | -49.96M |
| December 31, 2021 | -21.81M |
| September 30, 2021 | -15.59M |
| June 30, 2021 | -16.36M |
| Date | Value |
|---|---|
| March 31, 2021 | -15.81M |
| December 31, 2020 | -10.38M |
| September 30, 2020 | -9.61M |
| June 30, 2020 | -6.833M |
| March 31, 2020 | -5.341M |
| December 31, 2019 | -5.357M |
| September 30, 2019 | -4.272M |
| June 30, 2019 | -5.348M |
| March 31, 2019 | -4.111M |
| December 31, 2018 | -3.708M |
| September 30, 2018 | -2.755M |
| June 30, 2018 | -2.276M |
| March 31, 2018 | -2.15M |
| December 31, 2017 | -1.393M |
| September 30, 2017 | -5.273M |
| June 30, 2017 | -0.759M |
| March 31, 2017 | -0.494M |
| December 31, 2016 | -0.627M |
| September 30, 2016 | -0.322M |
| June 30, 2016 | -0.201M |
| March 31, 2016 | 0.00 |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Ionis Pharmaceuticals, Inc. | -109.97M |
| Ultragenyx Pharmaceutical, Inc. | -118.00M |
| BridgeBio Pharma, Inc. | -60.50M |
| Cytokinetics, Inc. | -190.07M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 127.34M |
| Total Expenses (Quarterly) | 64.27M |
| EPS Diluted (Quarterly) | 2.045 |
| Enterprise Value | 8.154B |
| Gross Profit Margin (Quarterly) | 92.91% |
| Profit Margin (Quarterly) | 49.53% |
| Earnings Yield | 2.41% |
| Operating Earnings Yield | 2.44% |
| Normalized Earnings Yield | 2.413 |